Amylyx Pharmaceuticals AMLX

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.27 (+7.48%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Amylyx Pharmaceuticals (AMLX)
    Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $3.87

    • Market Cap

      $342.89 Million

    • Price-Earnings Ratio

      -0.87

    • Total Outstanding Shares

      88.60 Million Shares

    • Total Employees

      123

    • Dividend

      $0.42 Per Share Quarterly

    • IPO Date

      January 7, 2022

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      43 thorndike street, Cambridge, MA, 02141

    • Homepage

      https://www.amylyx.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Net Cash Flow From Financing Activities$348,000
    Exchange Gains/Losses$-438,000
    Net Cash Flow From Financing Activities, Continuing$348,000
    Net Cash Flow$-92.08 Million
    Net Cash Flow From Operating Activities$-167.65 Million
    Net Cash Flow, Continuing$-91.64 Million

    Income Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Net Income/Loss Available To Common Stockholders, Basic$-301.74 Million
    Other Operating Expenses$177.73 Million
    Costs And Expenses$402.10 Million
    Selling, General, and Administrative Expenses$114.33 Million
    Net Income/Loss Attributable To Parent$-301.74 Million
    Basic Earnings Per Share$-4.43

    Comprehensive Income

    January 1, 2024 to December 31, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss$-302.03 Million
    Other Comprehensive Income/Loss Attributable To Parent$-289,000
    Comprehensive Income/Loss Attributable To Parent$-302.03 Million
    Other Comprehensive Income/Loss$-289,000

    Balance Sheet

    January 1, 2024 to December 31, 2024
    MetricValue
    Assets$193.63 Million
    Current Liabilities$28.41 Million
    Noncurrent Assets$4.20 Million
    Liabilities And Equity$193.63 Million
    Liabilities$28.87 Million
    Accounts Payable$2.94 Million

    Historical Dividends

    Current dividend: $0.42 Per Share Quarterly
    Announcement DatePayment DateRecord DateAmountFrequency
    Jan 25, 2018Apr 2, 2018Mar 29, 2018$0.41965Quarterly
    Dec 27, 2017Jan 2, 2018Dec 29, 2017$0.3556285Quarterly

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about AMLX from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.